Prevymis® (letermovir) – New indication
June 6, 2023 - Merck announced the FDA approval of Prevymis (letermovir), for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).
Download PDF
